Who owns DOC GENERICI?

DOC GENERICI has been 100% owned by CHARTERHOUSE since July 2013.

At what enterprise value was DOC GENERICI acquired in 2013?

During the acquisition of DOC GENERICI by CHARTERHOUSE in 2013, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of DOC GENERICI when it was acquired by CHARTERHOUSE?

The estimated EV/EBITDA multiple for DOC GENERICI is in the range of 5x - 12x.

When was DOC GENERICI acquired by CHARTERHOUSE?

DOC GENERICI was acquired by CHARTERHOUSE in 2013.

What was the revenue of DOC GENERICI at the time of the deal?

The revenue of DOC GENERICI at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of DOC GENERICI during the acquisition?

DOC GENERICI's EBITDA is estimated to be in the range of 25M - 50M EUR.

How is the data for the DOC GENERICI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOC GENERICI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://bebeez.it/non-categorizzato/charterhouse-sigla-lacquisizione-di-doc-generici-con-175-milioni-di-linee-di-credito/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaDOC GENERICI

07/2013

DOC GENERICI acquired by CHARTERHOUSE

ITALY Life Sciences / Pharma & Biotech / Generics / Labs EV 300M - 700M EUR

Context

Charterhouse acquired 100% of DOC Generici from a consortium of three pharmaceutical companies: Apotex (Canada), Chiesi Farmaceutici (Italy), and Zambon (Italy). The deal was structured as a Management Buyout, backing the incumbent CEO. It was financed with approximately EUR175 million in debt facilities provided by UniCredit (acting as Global Coordinator), HSBC, and Intesa Sanpaolo. The strategic aim was to professionalize the entity from a trade-owned subsidiary into an independent market leader, expanding its product pipeline and diversifying into segments like nutritional supplements.

DOC GENERICI, which reported an EBITDA margin of in 2012, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

DOC Generici is Italy's leading independent generic pharmaceutical company. It operates an asset-light model, focusing on the marketing and distribution of a vast portfolio of out-of-patent drugs across multiple therapeutic areas (cardiovascular, gastrointestinal, metabolic). It holds one of the largest market shares in the Italian retail pharmacy channel.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2012

2011

Other operations with DOC GENERICI

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2022	TPG	DOC GENERICI	ITALY	Generics / Labs
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
03/2016	CVC	DOC GENERICI	ITALY	Generics / Labs

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOC GENERICI by CHARTERHOUSE are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: charterhouse